Concomitant use of anticholinergics with acetylcholinesterase inhibitors in medicaid recipients with dementia and residing in nursing homes

Brief reports

Ankita Modi, Michael Weiner, Bruce A. Craig, Laura P. Sands, Marc Rosenman, Joseph Thomas

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

OBJECTIVES: To evaluate the extent of concomitant use of anticholinergic and cholinesterase inhibitor medications in Medicaid recipients with dementia residing in nursing homes. DESIGN: Cross-sectional survey of medical claims data. SETTING: Indiana Medicaid claims for 2004. PARTICIPANTS: Indiana Medicaid recipients continuously eligible for Medicaid in 2004 aged 65 and older with dementia who were residing in nursing homes and taking cholinesterase inhibitors. MEASUREMENTS: Rates of concomitant anticholinergic and cholinesterase inhibitor use, number of days residents experienced concomitant use, and concomitant use according to therapeutic class and level of anticholinergic activity were determined. RESULTS: A large proportion (46.7%) of 3,251 Medicaid beneficiaries living in nursing homes and taking cholinesterase inhibitors received anticholinergics concomitantly. Anticholinergics designated as Level 3, or having markedly anticholinergic adverse effects, accounted for most of the concomitant anticholinergic use. More than half (58.1%) of the individuals with concomitant anticholinergic use had 100 or more days of such use. CONCLUSION: Nearly half of Indiana Medicaid recipients with dementia residing in nursing homes who were taking cholinesterase inhibitors in 2004 were using anticholinergics concomitantly. Patterns of concomitant use in the population examined may assist practitioners in reviewing their prescribing decisions for this vulnerable population.

Original languageEnglish
Pages (from-to)1238-1244
Number of pages7
JournalJournal of the American Geriatrics Society
Volume57
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Cholinesterase Inhibitors
Medicaid
Cholinergic Antagonists
Nursing Homes
Dementia
Vulnerable Populations
Cross-Sectional Studies

Keywords

  • Acetylcholinesterase inhibitors
  • Anticholinergics
  • Cholinesterase inhibitors
  • Dementia

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Concomitant use of anticholinergics with acetylcholinesterase inhibitors in medicaid recipients with dementia and residing in nursing homes : Brief reports. / Modi, Ankita; Weiner, Michael; Craig, Bruce A.; Sands, Laura P.; Rosenman, Marc; Thomas, Joseph.

In: Journal of the American Geriatrics Society, Vol. 57, No. 7, 07.2009, p. 1238-1244.

Research output: Contribution to journalArticle

@article{b150ae0c708347bebaff62115b852c2a,
title = "Concomitant use of anticholinergics with acetylcholinesterase inhibitors in medicaid recipients with dementia and residing in nursing homes: Brief reports",
abstract = "OBJECTIVES: To evaluate the extent of concomitant use of anticholinergic and cholinesterase inhibitor medications in Medicaid recipients with dementia residing in nursing homes. DESIGN: Cross-sectional survey of medical claims data. SETTING: Indiana Medicaid claims for 2004. PARTICIPANTS: Indiana Medicaid recipients continuously eligible for Medicaid in 2004 aged 65 and older with dementia who were residing in nursing homes and taking cholinesterase inhibitors. MEASUREMENTS: Rates of concomitant anticholinergic and cholinesterase inhibitor use, number of days residents experienced concomitant use, and concomitant use according to therapeutic class and level of anticholinergic activity were determined. RESULTS: A large proportion (46.7{\%}) of 3,251 Medicaid beneficiaries living in nursing homes and taking cholinesterase inhibitors received anticholinergics concomitantly. Anticholinergics designated as Level 3, or having markedly anticholinergic adverse effects, accounted for most of the concomitant anticholinergic use. More than half (58.1{\%}) of the individuals with concomitant anticholinergic use had 100 or more days of such use. CONCLUSION: Nearly half of Indiana Medicaid recipients with dementia residing in nursing homes who were taking cholinesterase inhibitors in 2004 were using anticholinergics concomitantly. Patterns of concomitant use in the population examined may assist practitioners in reviewing their prescribing decisions for this vulnerable population.",
keywords = "Acetylcholinesterase inhibitors, Anticholinergics, Cholinesterase inhibitors, Dementia",
author = "Ankita Modi and Michael Weiner and Craig, {Bruce A.} and Sands, {Laura P.} and Marc Rosenman and Joseph Thomas",
year = "2009",
month = "7",
doi = "10.1111/j.1532-5415.2009.02258.x",
language = "English",
volume = "57",
pages = "1238--1244",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Concomitant use of anticholinergics with acetylcholinesterase inhibitors in medicaid recipients with dementia and residing in nursing homes

T2 - Brief reports

AU - Modi, Ankita

AU - Weiner, Michael

AU - Craig, Bruce A.

AU - Sands, Laura P.

AU - Rosenman, Marc

AU - Thomas, Joseph

PY - 2009/7

Y1 - 2009/7

N2 - OBJECTIVES: To evaluate the extent of concomitant use of anticholinergic and cholinesterase inhibitor medications in Medicaid recipients with dementia residing in nursing homes. DESIGN: Cross-sectional survey of medical claims data. SETTING: Indiana Medicaid claims for 2004. PARTICIPANTS: Indiana Medicaid recipients continuously eligible for Medicaid in 2004 aged 65 and older with dementia who were residing in nursing homes and taking cholinesterase inhibitors. MEASUREMENTS: Rates of concomitant anticholinergic and cholinesterase inhibitor use, number of days residents experienced concomitant use, and concomitant use according to therapeutic class and level of anticholinergic activity were determined. RESULTS: A large proportion (46.7%) of 3,251 Medicaid beneficiaries living in nursing homes and taking cholinesterase inhibitors received anticholinergics concomitantly. Anticholinergics designated as Level 3, or having markedly anticholinergic adverse effects, accounted for most of the concomitant anticholinergic use. More than half (58.1%) of the individuals with concomitant anticholinergic use had 100 or more days of such use. CONCLUSION: Nearly half of Indiana Medicaid recipients with dementia residing in nursing homes who were taking cholinesterase inhibitors in 2004 were using anticholinergics concomitantly. Patterns of concomitant use in the population examined may assist practitioners in reviewing their prescribing decisions for this vulnerable population.

AB - OBJECTIVES: To evaluate the extent of concomitant use of anticholinergic and cholinesterase inhibitor medications in Medicaid recipients with dementia residing in nursing homes. DESIGN: Cross-sectional survey of medical claims data. SETTING: Indiana Medicaid claims for 2004. PARTICIPANTS: Indiana Medicaid recipients continuously eligible for Medicaid in 2004 aged 65 and older with dementia who were residing in nursing homes and taking cholinesterase inhibitors. MEASUREMENTS: Rates of concomitant anticholinergic and cholinesterase inhibitor use, number of days residents experienced concomitant use, and concomitant use according to therapeutic class and level of anticholinergic activity were determined. RESULTS: A large proportion (46.7%) of 3,251 Medicaid beneficiaries living in nursing homes and taking cholinesterase inhibitors received anticholinergics concomitantly. Anticholinergics designated as Level 3, or having markedly anticholinergic adverse effects, accounted for most of the concomitant anticholinergic use. More than half (58.1%) of the individuals with concomitant anticholinergic use had 100 or more days of such use. CONCLUSION: Nearly half of Indiana Medicaid recipients with dementia residing in nursing homes who were taking cholinesterase inhibitors in 2004 were using anticholinergics concomitantly. Patterns of concomitant use in the population examined may assist practitioners in reviewing their prescribing decisions for this vulnerable population.

KW - Acetylcholinesterase inhibitors

KW - Anticholinergics

KW - Cholinesterase inhibitors

KW - Dementia

UR - http://www.scopus.com/inward/record.url?scp=67649786739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649786739&partnerID=8YFLogxK

U2 - 10.1111/j.1532-5415.2009.02258.x

DO - 10.1111/j.1532-5415.2009.02258.x

M3 - Article

VL - 57

SP - 1238

EP - 1244

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 7

ER -